Search

Displaying results 2301 - 2310 of 4190 in total
  1. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. … In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control

  2. Drug

    Pipendoxifene

    go.drugbank.com/drugs/DB05414
    Investigational

    ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent pre...

  3. Drug

    Bucindolol

    go.drugbank.com/drugs/DB12752
    Investigational

    Bucindolol has been investigated in Heart Failure.

  4. Drug

    Tivantinib

    go.drugbank.com/drugs/DB12200
    Investigational

    Tivantinib has been investigated in Solid Tumors.

  5. Drug

    5-amino-1,3,4-thiadiazole-2-thiol

    go.drugbank.com/drugs/DB12348
    Investigational

    ATT has been investigated in Pulmonary Tuberculosis.

  6. Drug

    Ilaprazole

    go.drugbank.com/drugs/DB11964
    Investigational

    Ilaprazole has been investigated in Helicobacter Infections.

  7. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene. … Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757]

  8. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain ...

  9. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain ...

  10. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.